1-2 of 2
Laure van Steenbergen
Close
Sort by
Journal Articles

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Diana Cortes-Selva, Tineke Casneuf, Deeksha Vishwamitra, Sarah Stein, Tatiana Perova, Sheri Skerget, Elena Ramos, Laure van Steenbergen, Dries De Maeyer, Rengasamy Boominathan, Onsay Lau, Cuc Davis, Arnob Banerjee, Tara Stephenson, Clarissa M. Uhlar, Rachel Kobos, Jenna D. Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Usmani, Nizar Jacques Bahlis, Niels WCJ Van De Donk, Raluca Verona
Journal: Blood
Blood (2022) 140 (Supplement 1): 241–243.
https://doi.org/10.1182/blood-2022-162709
Published: 2022
Journal Articles

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Christie P.M. Verkleij, Kristine A. Frerichs, Carolien Duetz, Sonja Zweegman, Paola M. Homan-Weert, Monique C. Minnema, Annemiek Broyl, Mark-David Levin, Gerard M.J. Bos, Marie José Kersten, Saskia K. Klein, Medya M. Shikhagaie, Maria Krevvata, Tineke Casneuf, Yann Abraham, Raluca I. Verona, Tina Smets, Greet Vanhoof, Diana Cortes-Selva, Laure van Steenbergen, Diego Vieyra, Pieter Sonneveld, Tuna Mutis, Niels W.C.J. van de Donk
Journal: Blood
Blood (2021) 138 (Supplement 1): 728.
https://doi.org/10.1182/blood-2021-150913
Published: 2021